Zobrazeno 1 - 10
of 1 315
pro vyhledávání: '"nafamostat"'
Publikováno v:
Journal of Intensive Medicine, Vol 4, Iss 4, Pp 453-467 (2024)
Sepsis is a life-threatening syndrome resulting from a dysregulated host response to infection. It is the primary cause of death in the intensive care unit, posing a substantial challenge to human health and medical resource allocation. The pathogene
Externí odkaz:
https://doaj.org/article/a97b8a3d845c452cb041e0865b42d325
Publikováno v:
BMC Nephrology, Vol 25, Iss 1, Pp 1-2 (2024)
Abstract We are writing to you in response to the article published in BMC Nephrology titled “Dose of nafamostat mesylate during continuous kidney replacement therapy in critically ill patients: a two-centre observational study”. The study provid
Externí odkaz:
https://doaj.org/article/24129f7c383742a4a8fe6e3b56448b97
Autor:
Shinya Kameda, Akinori Maeda, Shun Maeda, Yutaro Inoue, Kazunari Takahashi, Akira Kageyama, Kent Doi, Tomoko Fujii
Publikováno v:
BMC Nephrology, Vol 25, Iss 1, Pp 1-7 (2024)
Abstract Background Nafamostat mesylate is an anticoagulant used for critically ill patients during continuous kidney replacement therapy (CKRT), characterised by its short half-life. However, its optimal dosage remains unclear. This study aimed to e
Externí odkaz:
https://doaj.org/article/a84bd85e7d294691b2cdae00637a191e
Publikováno v:
Linchuang shenzangbing zazhi, Vol 24, Iss 2, Pp 96-102 (2024)
ObjectiveTo explore the efficacy and safety of nafamostat mesylate (NM) in patients on continuous renal replacement therapy (CRRT) at a high risk of hemorrhage.MethodsFrom March 2021 to February 2022, a retrospective study was conducted for 61 CRRT p
Externí odkaz:
https://doaj.org/article/d9edf56787b44e72ac1bb436685f41aa
Publikováno v:
JA Clinical Reports, Vol 10, Iss 1, Pp 1-5 (2024)
Abstract Background Andexanet alfa, an anti-Xa inhibitor antagonist, induces heparin resistance. Here, we report a case of successful management of cardiopulmonary bypass with andexanet alfa-induced heparin resistance using nafamostat mesylate. Case
Externí odkaz:
https://doaj.org/article/e88434aa226b4480814a380549e27aa5
Publikováno v:
European Journal of Medical Research, Vol 29, Iss 1, Pp 1-9 (2024)
Abstract Purpose The choice of continuous renal replacement therapy (CRRT) anticoagulation program for patients at high risk of bleeding has always been a complex problem in clinical practice. Clinical regimens include regional citrate anticoagulatio
Externí odkaz:
https://doaj.org/article/ac518dd8792044a1a074b65a1e9c2c85
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Takahiro Yamamoto, Takuji Machida, Chiho Tanno, Shiori Hasebe, Mayu Tamura, Nanaka Kobayashi, Sachiko Hiraide, Naoya Hamaue, Kenji Iizuka
Publikováno v:
Journal of Pharmacological Sciences, Vol 152, Iss 2, Pp 90-102 (2023)
We aimed to clarify the effect of nafamostat mesilate (nafamostat) on intestinal mucositis as well as the potentiation of intestinal 5-hydroxytryptamine (5-HT) dynamics induced by methotrexate, an anti-cancer drug, in rats. Rats received intraperiton
Externí odkaz:
https://doaj.org/article/4e1bfa9e836d46dbb172d84c6045b8c1
Autor:
Yumiko Kawai, Chiharu Kinoshita, Koichi Matsuda, Keiko Takeuchi, Yoshimoto Inoue, Yoko Fujita
Publikováno v:
Renal Replacement Therapy, Vol 9, Iss 1, Pp 1-7 (2023)
Abstract Background CCE is a systemic disease with poor prognosis with no established treatment. Approximately 23–32% of CCE cases progress to end-stage renal failure, and the 1-year mortality rate of CCE with organ failure is 60–90%. The dialysi
Externí odkaz:
https://doaj.org/article/fa9a927edeae431188c7bfef47434f8b
Publikováno v:
Kosin Medical Journal, Vol 38, Iss 1, Pp 36-42 (2023)
Background Nafamostat mesylate is widely used as an anticoagulant in continuous renal replacement therapy (CRRT). The generic versions of nafamostat mesylate have identical main components to the original product. However, it is questionable whether
Externí odkaz:
https://doaj.org/article/025a85ced82e49dd9084ecef65b9b208